Sylvester Comprehensive Cancer Center

E-mail a Friend

Jonathan C. Trent, M.D., Ph.D.

General Information

Jonathan C. Trent, M.D., Ph.D.

Languages

  • English

CV

Specialties

  • Internal Medicine
  • Hematology/Oncology - Internal Medicine

Roles

  • Professor of Medicine, Co-Director Musculoskeletal Center, Sarcoma Medical Research Program

Clinical Interests

Sarcoma

Research Interests

 My Clinical research has focused on translational trials with substantial biologic correlates for patients with gastrointestinal stromal tumor, pigmented villonodular synovitis, liposarcomas, desmoid tumor, and more recently our two phase I clinical trials with the isocitrate dehydrogenase (IDH) inhibitor, AG-120 and AG-221, for patients with IDH mutant solid tumors such as chondrosarcoma.

Awards

Sarcoma Clinician of the Year: The Sarcoma Alliance
Outstanding Care Award: The Sarcoma Alliance
GIST Clinician of the Year: The LifeRaft Group
GIST Humanitarian of the Year: The LifeRaft Group
Nominated as the January educator of the month acknowledging educational roles at M. D. Anderson and the GSBS
Young Investigator Award, Connective Tissue Oncology Society
Award for Excellence in Research, The University of Texas M. D. Anderson Cancer Center Division of Cancer Medicine
National Institutes of Health Training Grant for Academic Oncology at M. D. Anderson Cancer Center (T32, CA09666
C. D. Howe Award For Excellence in Clinical Medical Oncology, The University of Texas M. D. Anderson Cancer Center Division of Cancer Medicine
National Cancer Institute Comprehensive Pre-doctoral Fellowship
University of Texas Medical School Honors in Immunology, Mechanism of Disease, Family Practice, Cancer Biology, Tumor Immunology
American Institute of Chemists-Outstanding Senior Student Award
Presidential Honor Roll at Southeastern Oklahoma State University

Education

1999-2002 Fellowship - Medical Oncology
University of Texas MD Anderson Cancer Center
1999 Residency
University of Texas Health Science Center
1995 PhD
The University of Texas Health Science Center
1988 PhD
Southeastern Oklahoma State University

Publications

  • Yang J, Ylip√§√§ A, Sun Y, Zheng H, Chen K, Nykter M, Trent JC, Ratner N, Lev DC, Zhang W. Genomic and Molecular Characterization of Malignant Peripheral Nerve Sheath Tumor Identifies the IGF1R Pathway as a Primary Target for Treatment. Clin Cancer Res. 2011 Oct 31. [Epub ahead of print] PubMed PMID: 22042973.
  • Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R. R1507, an Anti-Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antibody, and EWS/FLI-1 siRNA in Ewing's Sarcoma: Convergence at the IGF/IGFR/Akt Axis. PLoS One. 2011;6(10):e26060. Epub 2011 Oct 11. PubMed PMID: 22022506; PubMed Central PMCID: PMC3191161.
  • Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, Gronchi A, Corless CL, Goldstein D, Rubin BP, Maki RG, Lazar AJ, Lev D, Trent JC, von Mehren M. A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Ann Oncol. 2011 Oct 12. [Epub ahead of print] PubMed PMID: 21994214.
  • Dupart J, Zhang W, Trent JC. Gastrointestinal stromal tumor and its targeted therapeutics. Chin J Cancer. 2011 May;30(5):303-14. PubMed PMID: 21527063.
  • Yang J, Yang D, Sun Y, Sun B, Wang G, Trent JC, Araujo DM, Chen K, Zhang W. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. Cancer. 2011 Nov 1;117(21):4925-38. doi: 10.1002/cncr.26116. Epub 2011 Apr 14. PubMed PMID: 21495021.
  • Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011 Nov 1;117(21):4939-47. doi: 10.1002/cncr.26098. Epub 2011 Apr 8. PubMed PMID: 21480200; PubMed Central PMCID: PMC3135685.
  • Pisters PW, Blanke CD, von Mehren M, Picus J, Sirulnik A, Stealey E, Trent JC; on behalf of the reGISTry Steering Committee. A USA registry of gastrointestinal stromal tumor patients: changes in practice over time and differences between community and academic practices. Ann Oncol. 2011 Nov;22(11):2523-2529. Epub 2011 Apr 4. PubMed PMID: 21464155.
  • Wang WL, Conley A, Reynoso D, Nolden L, Lazar AJ, George S, Trent JC. Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor. Cancer Chemother Pharmacol. 2011 Jan;67 Suppl 1:S15-24. Epub 2010 Dec 24. Review. PubMed PMID: 21181476.
  • 11: Reynoso D, Nolden LK, Yang D, Dumont SN, Conley AP, Dumont AG, Zhou K, Duensing A, Trent JC. Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells. Mol Oncol. 2011 Feb;5(1):93-104. Epub 2010 Oct 16. PubMed PMID: 21115411.
  • Reynoso D, Trent JC. Neoadjuvant and adjuvant imatinib treatment in gastrointestinal stromal tumor: current status and recent developments. Curr Opin Oncol. 2010 Jul;22(4):330-5. Review. PubMed PMID: 20520542
  • Savar A, Trent J, Al-Zubidi N, Huh W, Anderson P, Shinder R, Esmaeli B. Efficacy of adjuvant and neoadjuvant therapies for adult orbital sarcomas. Ophthal Plast Reconstr Surg. 2010 May-Jun;26(3):185-9. PubMed PMID: 20489544.
  • Pandurengan RK, Dumont AG, Araujo DM, Ludwig JA, Ravi V, Patel S, Garber J, Benjamin RS, Strom SS, Trent JC. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol. 2010 Oct;21(10):2107-11. Epub 2010 Mar 26. PubMed PMID: 20348145; PubMed Central PMCID: PMC2946863.
  • Trent JC, Patel SS, Zhang J, Araujo DM, Plana JC, Lenihan DJ, Fan D, Patel SR, Benjamin RS, Khakoo AY. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer. 2010 Jan 1;116(1):184-92. PubMed PMID: 19885836.

E-mail a Friend